🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

359 results for “vaccine” Clear

  1. INO-4201

    INOVIO PHARMACEUTICALS, INC.

    Ebola Vaccine

    phase 1 mab completed

    1 trial

  2. Inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Infection; Viral, Enterovirus

    phase 1 mab completed

    1 trial

  3. Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    phase 1 mab completed

    1 trial

  4. Ipilimumab

    VACCINEX, INC.

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

    phase 1 mab active

    1 trial

  5. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  6. KRAS Vaccine with Poly-ICLC adjuvant

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  7. Low Dose MSH2-/- tumor cell vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    pMMR/MSS Advanced Colorectal Cancer

    phase 1 mab active

    1 trial

  8. Low-dose RSV mRNA vaccine

    Sinovac Research and Development Co.,

    RSV

    phase 1 mab active

    1 trial

  9. Mammaglobin-A DNA Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 mab active

    1 trial

  10. Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Meningitis, Meningococcal

    phase 1 mab active

    1 trial

  11. NDV-3 vaccine with alum IM

    United Therapeutics Europe Ltd

    Staphylococcal Infections

    phase 1 mab completed

    1 trial

  12. NoV GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Gastroenteritis

    phase 1 mab completed

    1 trial

  13. One dose of investigational vaccine

    Sinovac Research and Development Co.,

    Hepatitis B

    phase 1 mab completed

    1 trial

  14. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  15. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  16. Pneumococcal Vaccine, Polyvalent (23-valent)

    Praxis Precision Medicines

    HIV Infections

    phase 1 mab completed

    1 trial

  17. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab completed

    1 trial

  18. Recombinant SARS-CoV-2 Fusion Protein Vaccine

    Livzon Pharmaceutical Group

    COVID19

    phase 1 mab completed

    1 trial

  19. Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers

    BioNTech SE

    Tuberculosis

    phase 1 other active

    1 trial

  20. Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

    Takeda

    Healthy

    phase 1 mab completed

    1 trial

  21. Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants

    Lacuna Pharma Pty Ltd

    Clostridioides difficile (C. difficile)

    phase 1 other active

    1 trial

  22. Tuberculosis (TB) vaccine (Ad5-105K)

    CanSino Biologics

    Tuberculosis

    phase 1 mab active

    1 trial

  23. Tuberculosis Vaccine

    Biotech Pharmaceutical Co.,

    Tuberculosis

    phase 1 mab completed

    1 trial

  24. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources